News

Throughout July, the nonprofit Biliary Atresia Research & Education (BARE) is holding its Live and Let Live(r) fundraising campaign to raise money and awareness…

BiTS, an antibody co-developed by researchers at New York University (NYU) to tame overactive immune T-cells, reduced inflammation and liver damage in a study that…

Combined treatment with phenobarbital and ursodeoxycholic acid (UDCA) is superior to phenobarbital alone at treating cholestasis symptoms, and does so at a faster rate,…

Six months of treatment with lanifibranor, Inventiva’s experimental therapy, reduced abnormalities in liver sinusoidal endothelial cells (LSECs) in people with metabolic dysfunction-associated steatohepatitis (MASH),…

The hepatitis E virus (HEV) has long been known to infect liver cells, but researchers have now shown it is also able to infect…

About 40 in every 100,000 U.S. adults have primary biliary cholangitis (PBC), with its frequency, when adjusted to population size, being highest in some…

Nearly one in three patients diagnosed with intrahepatic cholestasis of pregnancy (ICP) during a first pregnancy will develop the condition again in a subsequent…

Pemvidutide resolved metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease, without worsening liver scarring (fibrosis) for more than half of people…

Biliary atresia, a rare liver disease affecting infants, may be diagnosed before birth using a novel artificial intelligence (AI) method that analyzes prenatal ultrasound…

The first participant has been dosed in a Phase 3 clinical trial testing Atea Pharmaceuticals’ combination therapy of bemnifosbuvir and ruzasvir in people with chronic…